First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis

PURPOSE: The addition of bevacizumab to fluorouracil-based chemotherapy is a standard of care for previously untreated metastatic colorectal cancer. Continuation of bevacizumab beyond progression is an accepted standard of care based on a 1.4-month increase in median overall survival observed in a r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Goldstein, Daniel A., Chen, Qiushi, Ayer, Turgay, Howard, David H., Lipscomb, Joseph, El-Rayes, Bassel F., Flowers, Christopher R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2015
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881313/
https://ncbi.nlm.nih.gov/pubmed/25691669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.58.4904
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars